ISABELA BARBOSA FIRIGATO

(Fonte: Lattes)
Índice h a partir de 2011
3
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/40 - Laboratório de Imunohematologia e Hematologia Forense, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: ANNE VICTORIO PESSOTTO ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 2 Citação(ões) na Scopus
    Association of Mu opioid receptor (A118G) and BDNF (G196A) polymorphisms with rehabilitation-induced cortical inhibition and analgesic response in chronic osteoarthritis pain
    (2023) GONCALVES, Fernanda de Toledo; PACHECO-BARRIOS, Kevin; REBELLO-SANCHEZ, Ingrid; CASTELO-BRANCO, Luis; MELO, Paulo S. de; PARENTE, Joao; CARDENAS-ROJAS, Alejandra; FIRIGATO, Isabela; PESSOTTO, Anne Victorio; IMAMURA, Marta; SIMIS, Marcel; BATTISTELLA, Linamara; FREGNI, Felipe
    Background/objective: Chronic pain due to osteoarthritis (OA) is a prevalent cause of global dis-ability. New biomarkers are needed to improve treatment allocation, and genetic polymorphisms are promising candidates. Method: We aimed to assess the association of OPRM1 (A118G and C17T) and brain-derived neurotrophic factor (BDNF [G196A]) polymorphisms with pain-related outcomes and motor cortex excitability metrics (measured by transcranial magnetic stimulation) in 113 knee OA patients with chronic pain. We performed adjusted multivariate regression analy-ses to compare carriers versus non-carriers in terms of clinical and neurophysiological character-istics at baseline, and treatment response (pain reduction and increased cortical inhibitory tonus) after rehabilitation. Results: Compared to non-carriers, participants with polymorphisms on both OPRM1 (A118G) and BDNF (G196A) genes were less likely to improve pain after rehabili-tation (85 and 72% fewer odds of improvement, respectively). Likewise, both carriers of OPRM1 polymorphisms (A118G and C17T) were also less likely to improve cortical inhibition (short intra-cortical inhibition [SICI], and intracortical facilitation [ICF], respectively). While pain and corti-cal inhibition improvement did not correlate in the total sample, the presence of OPRM1 (A118G) and BDNF (G196A) polymorphisms moderated this relationship. Conclusions: These results underscore the promising role of combining genetic and neurophysiological markers to endotype the treatment response in this population. (c) 2022 The Authors.